ADP-ribosylation Cycles

ADP-核糖基化循环

基本信息

项目摘要

Explanation The activity of poly-ADP-ribose polymerases (PARPs) is reversed by poly-ADP-ribose (PAR)-degrading enzymes, of which poly-ADP-ribose glycohydrolase (PARG) and ADP ribosylhydrolase 3 (ARH3) catalyze PAR-degradation in vitro and in cells. In humans and mice, four PARG isoforms result from alternative splicing of a single PARG gene. Of them, only the protein encoded by the full-length open reading frame (hPARG111 and mPARG110) localizes to the nucleus. Most PARG activity is detected in the cytosol, which is in apparent contradiction to the nuclear localization of PARP1, the most abundant and most active PARP. Knockout of the PARG gene is embryonic lethal, whereas mice that express PARG from a gene deleted in exons 2 and 3 (PARGexon2-3), which lack nuclear mPARG110 as well as the two cytosolic isoforms mPARG101 and mPARG98, are viable. This suggests a vital role of the small murine PARG isoform mPARG63. The human counterpart of mPARG63 is a 60 kDa-protein (hPARG60) that, in contrast to mice, lacks exon 5-encoded amino acids. Owing to alternative translational start sites, the transcripts encoding the small human and murine PARG isoforms were suggested to encode proteins, in which the N-terminal amino acids constitute a mitochondrial targeting sequence (MTS) that is masked in all other PARGs. We established the genetic background of a fifth human PARG isoform hPARG55, which results from a hitherto unrecognized alternative splicing event of the primary PARG transcript. In-depth localization analysis revealed hPARG55 to be the only isoform that is targeted to the mitochondrial matrix, where the presence of poly-ADP-ribose metabolism is debated. Surprisingly, hPARG55 is catalytically inactive both in vitro and in cells. The PAR-degrading activity of hPARG55 could be restored by reintroducing exon 5-encoded amino acids. These findings could be applied to hPARG60 that also lacks exon 5, but localizes to the cytosol. In wild-type mice, we identified a splicing event leading to a cytosolic 52 kDa-PARG isoform (mPARG52), which was so far only reported in the PARGexon2-3 mutant. This isoform lacks exon 4 (encoding the MTS) and a significant portion of exon 5 supporting the conclusion that the human and the murine PARG genes encode PARG isoforms with functions different from PAR-degradation. Given these findings, we investigated the role of ARH3 in PAR degradation in mitochondria. In cells from ARH3-/- mice, targeted expression of PARP1 activity in mitochondria lead to greater accumulation of PAR. Matrix-accumulated PAR in ARH3-/- cells was no longer subject to degradation. Downregulation of PARG gene expression in ARH3-/- cells did not affect the PAR-degrading activity in mitochondria. Thus, the PAR-degrading activity we previously identified within mitochondria is carried out by ARH3, suggesting a role of this enzyme in PAR metabolism.
解释 聚ADP-核糖聚合酶(PARP)的活性被聚ADP-核糖(PAR)降解酶逆转,其中聚ADP-核糖糖水解酶(PARG)和ADP核糖基水解酶3(ARH 3)在体外和细胞中催化PAR降解。 在人类和小鼠中,四种PARG同种型由单个PARG基因的选择性剪接产生。其中,只有全长开放阅读框编码的蛋白质(hPARG 111和mPARG 110)定位于细胞核。大多数PARG活性在胞质溶胶中检测到,这与PARP 1的核定位明显矛盾,PARP 1是最丰富和最活跃的PARP。PARG基因的敲除是胚胎致死性的,而从外显子2和3中缺失的基因(PARG外显子2 -3)表达PARG的小鼠是存活的,其缺乏核mPARG 110以及两种胞质同种型mPARG 101和mPARG 98。这表明小鼠PARG同种型mPARG 63的重要作用。mPARG 63的人类对应物是一种60 kDa的蛋白质(hPARG 60),与小鼠相反,它缺乏外显子5编码的氨基酸。由于替代的翻译起始位点,编码小的人类和小鼠PARG同种型的转录物被认为编码蛋白质,其中N-末端氨基酸构成在所有其他PARG中被掩蔽的线粒体靶向序列(MTS)。 我们建立了第五种人类PARG亚型hPARG 55的遗传背景,该亚型由初级PARG转录物的迄今未被识别的选择性剪接事件引起。深入的定位分析显示,hPARG 55是唯一的亚型,是针对线粒体基质,其中存在的聚ADP-核糖代谢的争论。令人惊讶的是,hPARG 55在体外和细胞中均无催化活性。hPARG 55的PAR降解活性可以通过重新引入外显子5编码的氨基酸来恢复。这些发现可以应用于也缺乏外显子5但定位于胞质溶胶的hPARG 60。在野生型小鼠中,我们鉴定了导致胞质52 kDa PARG同种型(mPARG 52)的剪接事件,迄今为止仅在PARGexon 2 -3突变体中报道。该亚型缺乏外显子4(编码MTS)和外显子5的显著部分,支持人和鼠PARG基因编码的PARG亚型具有不同于PAR降解的功能的结论。 鉴于这些发现,我们研究了ARH 3在线粒体PAR降解中的作用。在来自ARH 3-/-小鼠的细胞中,PARP 1活性在线粒体中的靶向表达导致PAR的更大积累。ARH 3-/-细胞中基质积累的PAR不再降解。ARH 3-/-细胞中PARG基因表达下调不影响线粒体中PAR降解活性。因此,我们先前在线粒体内鉴定的PAR降解活性是由ARH 3进行的,表明这种酶在PAR代谢中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joel Moss其他文献

Joel Moss的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joel Moss', 18)}}的其他基金

Adp-ribosylation Cycles
Adp-核糖基化循环
  • 批准号:
    6671691
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ADP-ribosylation Cycles
ADP-核糖基化循环
  • 批准号:
    7321530
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
Clinical and Translational Research
临床和转化研究
  • 批准号:
    8939865
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)
淋巴管平滑肌瘤病 (LAM) 发病机制的特征
  • 批准号:
    8557920
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ADP-ribosylation Cycles
ADP-核糖基化循环
  • 批准号:
    10008750
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ADP-ribosylation Cycles
ADP-核糖基化循环
  • 批准号:
    8158015
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
CHARACTERIZATION OF THE PATHOGENESIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
淋巴管平滑肌瘤病 (LAM) 发病机制的特征
  • 批准号:
    6290430
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF LUNG DISEASE
一氧化氮在肺部疾病发病机制中的作用
  • 批准号:
    6290428
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF LUNG DISEASE
一氧化氮在肺部疾病发病机制中的作用
  • 批准号:
    6432691
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:
ADP-ribosylation Cycles
ADP-核糖基化循环
  • 批准号:
    7154203
  • 财政年份:
  • 资助金额:
    $ 266.41万
  • 项目类别:

相似海外基金

Control of genomic integrity and virulence of Aspergillus fumigatus by ADP-ribosylation.
通过 ADP-核糖基化控制烟曲霉的基因组完整性和毒力。
  • 批准号:
    MR/X007472/1
  • 财政年份:
    2023
  • 资助金额:
    $ 266.41万
  • 项目类别:
    Fellowship
Understanding the impact of DNA ADP-ribosylation on telomere function in cancer cells
了解 DNA ADP-核糖基化对癌细胞端粒功能的影响
  • 批准号:
    10751121
  • 财政年份:
    2023
  • 资助金额:
    $ 266.41万
  • 项目类别:
Composition and function of telomeric multi-protein complexes and their regulation by ADP-ribosylation
端粒多蛋白复合物的组成和功能及其ADP-核糖基化的调节
  • 批准号:
    2748032
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
    Studentship
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10524783
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
Regulation of DNA repair by histone ADP-ribosylation
组蛋白 ADP 核糖基化调节 DNA 修复
  • 批准号:
    MR/W017350/1
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
    Research Grant
Regulation and function of site-specific protein poly-ADP-ribosylation
位点特异性蛋白质聚 ADP 核糖基化的调控和功能
  • 批准号:
    10668492
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
ADP-ribosylation of DNA in Mycobacterium tuberculosis
结核分枝杆菌 DNA 的 ADP-核糖基化
  • 批准号:
    BB/W016613/1
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
    Research Grant
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10610165
  • 财政年份:
    2022
  • 资助金额:
    $ 266.41万
  • 项目类别:
A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation
聚 ADP 核糖基化调节生物分子缩合的化学足迹方法
  • 批准号:
    10389853
  • 财政年份:
    2021
  • 资助金额:
    $ 266.41万
  • 项目类别:
Role of Transcription Factor ADP-ribosylation in Breast Cancer Biology
转录因子 ADP-核糖基化在乳腺癌生物学中的作用
  • 批准号:
    10593900
  • 财政年份:
    2021
  • 资助金额:
    $ 266.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了